JP2012520866A5 - - Google Patents

Download PDF

Info

Publication number
JP2012520866A5
JP2012520866A5 JP2012500328A JP2012500328A JP2012520866A5 JP 2012520866 A5 JP2012520866 A5 JP 2012520866A5 JP 2012500328 A JP2012500328 A JP 2012500328A JP 2012500328 A JP2012500328 A JP 2012500328A JP 2012520866 A5 JP2012520866 A5 JP 2012520866A5
Authority
JP
Japan
Prior art keywords
udca
pharmaceutically acceptable
acceptable salt
treatment
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012500328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520866A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/000551 external-priority patent/WO2010106420A1/en
Publication of JP2012520866A publication Critical patent/JP2012520866A/ja
Publication of JP2012520866A5 publication Critical patent/JP2012520866A5/ja
Pending legal-status Critical Current

Links

JP2012500328A 2009-03-17 2010-03-16 高用量のウルソデオキシコール酸で非アルコール性脂肪性肝炎を治療する方法 Pending JP2012520866A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16095509P 2009-03-17 2009-03-17
US61/160,955 2009-03-17
PCT/IB2010/000551 WO2010106420A1 (en) 2009-03-17 2010-03-16 Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid

Publications (2)

Publication Number Publication Date
JP2012520866A JP2012520866A (ja) 2012-09-10
JP2012520866A5 true JP2012520866A5 (enExample) 2013-05-02

Family

ID=42167374

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012500328A Pending JP2012520866A (ja) 2009-03-17 2010-03-16 高用量のウルソデオキシコール酸で非アルコール性脂肪性肝炎を治療する方法

Country Status (12)

Country Link
US (1) US20120071451A1 (enExample)
EP (1) EP2408457A1 (enExample)
JP (1) JP2012520866A (enExample)
KR (1) KR20120008034A (enExample)
CN (1) CN102361642A (enExample)
AU (1) AU2010224587A1 (enExample)
CA (1) CA2755708A1 (enExample)
IL (1) IL215195A0 (enExample)
MX (1) MX2011009757A (enExample)
RU (1) RU2011139643A (enExample)
WO (1) WO2010106420A1 (enExample)
ZA (1) ZA201107578B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
KR101401628B1 (ko) * 2012-12-24 2014-06-02 삼성제약공업주식회사 간기능 개선용 정제 및 그 제조 방법
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US10174289B2 (en) 2014-05-28 2019-01-08 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
KR102573865B1 (ko) * 2014-07-29 2023-09-05 센젠 하이타이드 바이오파마슈티컬 리미티드 베르베린 염, 우르소데옥시콜산 염 및 병용물, 이들의 제조 및 응용 방법
WO2016061464A1 (en) 2014-10-17 2016-04-21 Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intetine using pluripotent stem cells and methods of making and using same
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
CN107613968A (zh) * 2015-11-19 2018-01-19 欣耀生医股份有限公司 预防或治疗脂肪肝的药物组合物
US11066650B2 (en) 2016-05-05 2021-07-20 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
KR102546194B1 (ko) 2016-11-04 2023-06-21 칠드런즈 호스피탈 메디칼 센터 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
JP7068305B2 (ja) 2016-12-05 2022-05-16 チルドレンズ ホスピタル メディカル センター 結腸オルガノイドならびにその作製方法および使用方法
WO2018191673A1 (en) 2017-04-14 2018-10-18 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
CN110958878A (zh) * 2017-06-21 2020-04-03 诺华股份有限公司 用于治疗非酒精性脂肪性肝炎的licofligozin
CN111565798B (zh) 2017-10-10 2025-06-24 儿童医院医学中心 食道组织和/或类器官组合物及其制备方法
KR101887561B1 (ko) * 2017-11-15 2018-09-06 주식회사 대웅제약 간염 바이러스에 의해 유발된 간 섬유화의 개선을 위한 약학 조성물
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
WO2020023245A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
RU2686042C1 (ru) * 2018-09-04 2019-04-23 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ лечения неалкогольной жировой болезни печени при метаболическом синдроме
CA3112026A1 (en) 2018-09-12 2020-03-19 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
JP7610533B2 (ja) 2019-05-31 2025-01-08 チルドレンズ ホスピタル メディカル センター 造血幹細胞の生成および拡大方法
KR102401535B1 (ko) * 2019-07-30 2022-05-24 주식회사 고바이오랩 간 손상 예방, 개선, 또는 치료용 조성물
CA3148434A1 (en) * 2019-07-30 2021-02-04 Kobiolabs, Inc. Composition and method for preventing, alleviating, or treating liver injury
MX2022009182A (es) * 2020-01-28 2022-08-17 Shilpa Medicare Ltd Metodo de administracion del acido ursodeoxicolico.
CN116782898A (zh) * 2020-10-23 2023-09-19 深圳君圣泰生物技术有限公司 小檗碱熊去氧胆酸盐的组合物及其用于治疗脂肪性肝病、糖尿病和高脂血症的方法
CN115137732A (zh) * 2021-03-29 2022-10-04 中国科学院大连化学物理研究所 Gpr120受体激动剂及熊去氧胆酸的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297229B1 (en) * 1994-11-14 2001-10-02 Mayo Foundation For Medical Education And Research Use of ursodeoxycholic acid to treat nonalcoholic steatohepatitis

Similar Documents

Publication Publication Date Title
JP2012520866A5 (enExample)
RU2011139643A (ru) Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты
JP2014528474A5 (enExample)
JP2018507914A5 (enExample)
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
JP2015524444A5 (enExample)
JP2010513360A5 (enExample)
JP2010518122A5 (enExample)
JP2013541583A5 (enExample)
JP2010525050A5 (enExample)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
WO2008011426A3 (en) Methods and medicaments for administration of ibuprofen
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
MX2012008652A (es) Terapias para tratar infeccion por virus de hepatitis c.
JP2011046708A5 (enExample)
JP2009517411A5 (enExample)
JP2011500589A5 (enExample)
EA201001100A1 (ru) Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение
JP2013501049A5 (enExample)
JP2016505050A5 (enExample)
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
JP2013511287A5 (enExample)
JP2009506043A5 (enExample)